Acme United Starts Off 2014 With Solid First Quarter Performance post image

Acme United’s (ACU – $17.50) sales during the three months ended March 31, 2014, reached $19.2 million, up 9% compared with sales of $17.7 million in the first quarter of 2013. Net income in the first quarter of 2014 rose by 19 percent to $368,000, or $0.11 per diluted share, versus $309,000, or $0.10 per diluted share, in the comparable quarter last year.

The revenue increase can especially be attributed to initial sales to Sam’s Club and Walmart of the Clauss lawn and gardening tools, sold under the Scotts and MiracleGro brands. In addition, strong sales growth was noted by Pac-Kit and PhysiciansCare first aid products, where traditional office supply customers, like Office Depot and OfficeMax, look to offer products outside their core office supplies.

During the earnings conference call, Walter C. Johnsen, the Company’s Chairman and CEO, confirmed the 2014 sales and earnings guidance. Sales are expected to reach between $97 and $102 million, an increase of between 8 and 14 percent. At the same time, the Company foresees earnings of [click to continue…]

Small Cap Updates & New Recommendations – April 5, 2014 post image

This week we have updates on Enterprise Group (E), Global Minerals (CTG) and IsoRay (ISR).

Enterprise Group (E – $1.02), a consolidator of construction services companies operating in the energy, utility and transportation infrastructure industries, announced strong financial results for its fiscal year 2013.

Revenues for 2013 reached $34.8 million, an increase of $16.3 million or 88%, compared with fiscal year 2012. This increase can mainly be attributed to the acquisition Calgary Tunnelling & Horizontal Augering Ltd. (“CTHA”) in June 2013, as well as expansion of Enterprise’s service equipment fleet, which has allowed the Company to both increase its capacity and attract projects from major customers.

Thanks to the significant increase in revenues, EBITDAS increased from $4.4 million in 2012 to $10.0 million in 2013. Earnings per share were $0.08 for 2013, an increase of $0.04 when compared to the prior year.

Looking ahead, Enterprise expects that the performance of its Utilities/Infrastructure Division will continue to improve. During 2013, this Division renewed a three year, multi-million dollar service contract with one of Canada’s premier [click to continue…]

IsoRay logo

IsoRay Inc’s (ISR – $2.42) stock price went through the roof this week as it announced the world’s first successfully completed pediatric implant using IsoRay Medical’s Cesium-131 brachytherapy mesh.

We first featured IsoRay on Smallcaps Investment Research two months ago at 75 cents because we felt that a company with such a valuable technology and an FDA approved product was significantly undervalued with a market cap of only $30 million. Although it’s gone way faster than expected, it’s nice to see that the market recognizes these facts.

Dr. Anthony Crimaldi at Levine Cancer Institute, Charlotte, NC, said “The patient was a 12 year old male who was diagnosed with recurrent metastatic Wilms tumor (a type of childhood kidney tumor) in the pleural space of the lower aspect of his left chest. Prior to this he had been treated extensively, but nevertheless the cancer returned.

Due to previous irradiation of his chest (specifically whole lung irradiation), the patient was not a candidate for either SBRT (stereotactic radiosurgery) or proton therapy for treatment of this lesion. Although surgical removal of the tumor was possible, radiation therapy was needed in this case to treat the surgical bed.

I worked closely with IsoRay to design a custom mesh containing Cesium-131 sources and we were able to place the mesh at the time of surgery so as not to expose critical [click to continue…]